ARTICLE | Product Development
COVID-19 update: gaps persist between U.S. test capacity rhetoric, reality; BARDA funds Hologic’s high-throughput assay
BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.
March 10, 2020 12:17 AM UTC
Updated on Mar 25, 2020 at 11:44 PM UTC
COVID-19 testing capacity in the U.S. is ramping up slowly, but huge gaps remain between needs and capacity, and between government claims and reality.
Delays in creating test capacity caused by incompetence at CDC and poor decisions at FDA have contributed to the public health crisis, a BioCentury editor’s note contends (see “Coronavirus Crisis Calls for Competence, Clarity and Courage at the Top”). ...